An interventional study of PET-Neck Parkinsonian patients in Parkinson Disease, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Recruiting at 1 site in Italy. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-03-01.
Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Parkinson Disease by Fondazione Policlinico Universitario Agostino Gemelli IRCCS — 9 open to participants now, 9 under way, none of them phase 3. Parkinson Disease · Fondazione Policlinico Universitario Agostino Gemelli IRCCS.
Among the 14 studies in Parkinson Disease by Fondazione Policlinico Universitario Agostino Gemelli IRCCS, this one is the 10th largest by planned enrollment of the 10 interventional ones that give a count, is one of 4 that started in 2023, is one of 10 with no phase, and was the 1st registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →9 of the 14 studies in Parkinson Disease by Fondazione Policlinico Universitario Agostino Gemelli IRCCS are open now, in 1 country. Recruiting first, the newest first:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 30–80
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 30–80
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18 mo+
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+ · Healthy volunteers
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18–80
By country, each count listing its studies:
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 30 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 4 started in 2023.
This study's planned enrollment of 18 is below the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 53 across the 10 interventional studies, 57 across the 4 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS is the lead sponsor of 953 studies on the registry; 541 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Parkinson Disease by Fondazione Policlinico Universitario Agostino Gemelli IRCCS, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In several neurodegenerative diseases, such as Parkinson's disease, the progressive loss of neurons of monoaminergic systems leads to the development of characteristic clinical manifestations.
Therefore, since the discovery that neurodegenerative phenomena are the basis of these Central Nervous System (CNS) diseases, re-innervation strategies have been studied that would allow to stop or at least slow down neurodegenerative phenomena, restoring lost catecholaminergic transmission.
Cell therapy in Parkinson's disease aims to treat motor disorders, but should not affect cognitive disorders that result from pathological alterations external to CNS and affecting other transmission systems, such as noradrenergic and cholinergic. These limitations lead to the search for new approaches based on the use of different cell types, but currently these scenarios still seem far away.
The theme of cerebral re-innervation in the treatment of neurodegenerative diseases is at the center of numerous translational and clinical research studies, developed according to various approaches and models, which testify to all the complexity and charm of the subject. Among the possible sources for a catecholamine reinnervation in Parkinson's disease, Superior Cervical Ganglion (SCG) could represent a valid autologous source: however, there is no functional evaluation in the literature that expresses the involvement or not of the ganglion in the neurodegenerative process.
This clinical study project is the first and essential phase of a larger project aimed at verifying the possibility of autologous catecholamine reinnervation in degenerative diseases of the CNS using the peripheral catecholamine system and in particular the superior cervical ganglion (GCS).
The aim of this project is to evaluate whether the peripheral catecholaminergic system, and in particular the SCG, is involved in the process of neurodegeneration. For this purpose, for an "in vivo" functional study, the suitability of the PET-CT 68Ga-PSMA examination will be studied in particular.
(visit 2) Review of inclusion and exclusion criteria. Neurological evaluation Patients will undergo a complete neurological examination by a neurologist experienced in movement disorders. The inclusion criteria for this study will be verified, including the correctness of the diagnosis according to the MDS diagnostic criteria. The stage of the disease will be quantified with staging according to Hoehn and Yahr. Motor symptoms, the impact of the disease on activities of daily living, neuropsychiatric disorders and the possible presence of motor fluctuations will be quantified with the Unified Parkinson's Disease Rating scale, part I, II, III and IV. In addition, patients will be evaluated with the Mini mental Status Evaluation for cognitive impairment screening.
The neurological evaluation will be performed a maximum of three months after the imaging examinations. Neurological evaluation will also be performed on patients in the control group, in order to exclude a diagnosis of PD.
(visit 3) Neuroradiology The craniocervical MRI protocol includes the sequences: axial T2 and T1 FSE/TSE, coronal T2 FSE/TSE with adipose signal saturation, axial T1 FSE/SE pre- and post-contrast (standard dose of paramagnetic MDC), 3D isotropic T1 with fat saturation, axial DWI (b 0-1000).
The acquisition thicknesses will not exceed 3mm with a gap of 10%. 3D-STIR sequences will also be used on the 3T.
MRI examination will be performed only on patients in the PD group.
Similarly, radiopharmaceutical uptake for PSMA has also been found in celiac, cervicothoracic (stellate) and sacral sympathetic ganglia. Histological studies have demonstrated increased GCII expression by non-myelin Schwann cells of the sympathetic nervous system ganglia . Rather limited in the literature are the studies that have analyzed the physiological greed of 68Ga-PSMA by celiac, stellate and sacral ganglia, as a potential cause of false positive findings on multimodal PET/CT or PET-MR imagin. Moreover, the uptake of 68Ga-PSMA in the superior cervical ganglion (GCS) has been analyzed only in very recent times [1].
In the present study, PET-CT imaging with 68Ga-PSMA will be used to assess the extent to which GCS uptake radiopharmaceutical for PSMA in Parkinson's disease patients. The exam will be performed at the PET Center of the Fondazione Policlinico Universitario Agostino Gemelli-IRCCS, Rome. The acquisition of the study will be performed by PET-CT tomograph 80 minutes after the administration of 68Ga-PSMA. The PET images will be evaluated independently by two Nuclear Physicians, after fusion with the MRI images for the correct anatomical localization of the GCS. After a preliminary qualitative (visual) analysis of the radiopharmaceutical uptake, a semi-quantitative evaluation will be carried out by positioning the Volume of Interest (VOI) on each of the GCS in order to calculate the Standardized Uptake Value (SUVmax). These values will be compared with those obtained in patients with prostate cancer undergoing PET-CT with 68Ga-PSMA at the same Center.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Brain and neck PET-CT with 68Ga-PSMA scan would be administered
Diagnostic Test: PET-Neck Parkinsonian patients
Brain and neck PET-CT scan with 68Ga-PSMA to detect metabolism in the Superior Cervical Ganglion of both sides.
Capacity of the Superior Cervical Ganglion in parkinsonian patients
The capacity of the Ganglion would be assessed through the analysis of degree of captation (68Ga-CTPET)
Time frame: through study completion, an average of 3 years
Started Jan 2023 (actual). Primary completion is estimated for Dec 2025, 35 months after the start.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 35 months is above that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS →